This model is characterized by the development of MPD with a median survival of 10 months (96), and cooperates with other common AML mutations, including NPM1c and mutant Wt1, to generate AML or accelerate the MPD disease process (97, 98). The gene discussed is WT1; the disease is myeloproliferative disorder.